Head-to-head dispatch
Hers vs Medro
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
Women-focused telehealth brand from Hims and Hers offering compounded semaglutide on a 6-month plan.
Marked down on: Limited public information on program details
FDAWarning letter issued to Hims & Hers Health, Inc. dba Hers in September 2025. See the FDA warning-letter database.
Desk Score
Medro (Medro Health Technologies, Inc.) is a telehealth brand whose GLP-1 program offers compounded semaglutide and tirzepatide, plus brand-name GLP-1s when eligible, via a partner medical group and…
Marked down on: Does not name its compounding pharmacy or its clinical partner medical group, so the fulfillment chain is not verifiable.
Hers takes this head-to-head with the higher Desk Score, 76/100 (C) against 71/100 (C) for Medro. Medro still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
Hers
76/100
C
Medro
71/100
C
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | Hers | Medro |
|---|---|---|
| Semaglutide | $199/mo (starting dose, compounded) | $199/mo (compounded) |
| Tirzepatide | $299/mo (starting dose, plus a separate fee, brand-name) | $299/mo (compounded) |
| Coverage | All 50 states | All 50 states |
| Brand-name | Yes | Yes |
| Oral option | Injectable only | Injectable only |
| Best for | Readers who want mainstream telehealth GLP-1 access. | Readers who want compounded or brand semaglutide/tirzepatide with transparent tiered pricing and no membership, all 50 states. |
| Desk Score | 76/100C | 71/100C |
The verdict
Desk pick — HersHers takes this head-to-head with the higher Desk Score, 76/100 (C) against 71/100 (C) for Medro. Medro still holds its ground where its strengths line up with yours.
Choose Hers if…
Readers who want mainstream telehealth GLP-1 access.
$199/mo (starting dose, compounded) sema · $299/mo (starting dose, plus a separate fee, brand-name) tirz · All 50 states
FDAWarning letter issued to Hims & Hers Health, Inc. dba Hers in September 2025. See the FDA warning-letter database.
Choose Medro if…
Readers who want compounded or brand semaglutide/tirzepatide with transparent tiered pricing and no membership, all 50 states.
$199/mo (compounded) sema · $299/mo (compounded) tirz · All 50 states
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we file on a provider reads the same either way. Read full breakdowns: Hers · Medro.
Also here
CoreAge Rx tops every dispatch at 94/100
Whichever of these two you lean toward, the Desk's #1-rated provider outscores them both. The Desk's top dispatch: flat all-in pricing, both molecules, all 50 states — no teaser-rate traps.
More head-to-heads
- Hers vs CoreAge Rx
- Medro vs Vaylen
- Hers vs Strut Health
- Medro vs Ondra Health
- Hers vs Invigor Medical
- Medro vs Vytora Health
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.